Table 3.

Patient Sociodemographic and Clinical Predictors of Chronic Kidney Disease Care*

	Kidney disease monitoring, %		Cardiovascular disease management, %
Predictor	Annual eGFR	Annual urine protein	ACE-I/ ARB use‡	Blood pressure <130/80 mmHg	Annual LDL cholesterol	Statin use§	LDL <100 mg/dl
Patient age
≤65 years	89.2	20.7	68.9	56.9*	73.7	39.2	38.7*
>65 years	88.5	20.0	71.5	52.9	75.8	43.1	46.1
Patient race
Black	87.9	22.7	73.3	46.1*	72.4*	41.3	32.3*
Other race	89.4	25.7*	73.9	53.8	75.8	42.4	41.0*
White (reference)	89.1	19.5	70.4	54.6	75.5	41.8	45.6
Patient gender
Male	89.1	24.4*	72.2	56.5*	76.6*	39.4	51.4*
Female	89.0	17.7	70.1	52.2	74.5	42.9	39.7
Insurance
Medicare	89.7	20.1	69.8*	54.6	74.6	42.0	44.8
Medicaid	90.1	23.3	76.5	48.6	82.9*	42.4	48.5
Uninsured	63.6*	6.2*	57.5*	57.9	45.1*	35.7	25.7*
Commercial (reference)	87.7	20.9	74.2	52.4	77.2	41.7	43.2
Comorbid conditions
Diabetes
Present	92.8*	76.1*	81.7*	57.0*	85.6*	65.6*	66.0*
Absent	88.4	8.2	62.1	52.6	69.9	37.9	35.5
Hypertension
Present	91.9*	23.8*	73.5*	50.1*	78.4*	47.5*	48.2*
Absent	81.1	14.3	41.7	61.2	68.5	34.4	36.8
CAD†
Present	89.9*	19.8	71.7	57.0*	76.4*	51.8*	51.9*
Absent	88.2	20.5	70.1	50.9	74.3	37.1	37.1

*Percentages in bold indicate statistically significant differences with p <0.05 after adjusting for patient age, race, gender, insurance status, diabetes, hypertension, coronary artery disease, nephrology co-management and presence of CKD on the problem list

†Denotes coronary artery disease

‡Among 8,045 patients with coexisting diabetes, hypertension or microalbuminuria. ACE-I denotes angiotensin-converting enzyme inhibitor, ARB denotes angiotensin receptor blocker

§Use of HMG Co-A reductase inhibitors among 4,645 patients with LDL cholesterol >100 mg/dl